Literature DB >> 16182110

Reduced mRNA and protein content of rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension.

Elisa Pagnin1, Andrea Semplicini, Michelangelo Sartori, Achille C Pessina, Lorenzo A Calò.   

Abstract

BACKGROUND: Activation of RhoA/Rho kinase (ROK) pathway by angiotensin II (Ang II) is involved in the pathophysiology of hypertension and remodeling. In Bartter's and Gitelman's syndrome (BS/GS), the short-term and long-term signaling of Ang II are blunted. The BS/GS have also reduced expression and response on Ang II challenge of ROK, which indicate downregulation of RhoA/ROK pathway. As causes for RhoA/ROK downregulation in BS/GS, we hypothesized an alteration at the level of the upstream regulators of RhoA such as reduced expression of Rho guanine nucleotide exchange factor (RhoGEF), which links activation of G protein-coupled receptors to RhoA/ROK signaling or increased guanine nucleotide dissociation inhibitor (RhoGDI), which inhibits dissociation of GDP from GDI maintaining RhoA in an inactive state.
METHODS: In mononuclear cells of 9 BS/GS and 9 healthy controls (C), we looked at gene and protein expression (reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot) of RhoA, RhoGEF, and RhoGDI.
RESULTS: In BS/GS RhoA gene and protein expression were not different from C. Also RhoGDI mRNA and protein levels were not different. On the contrary, p115RhoGEF mRNA and protein levels were reduced in BS/GS.
CONCLUSIONS: Reduced p115RhoGEF may explain the downregulation of RhoA/ROK pathway in BS/GS. This is the first report of upstream regulators of RhoA level in BS/GS, a human clinical condition characterized by reduced vascular tone regulation. Because BS/GS represent the mirror image of derangements involved in hypertension, the reduced RhoGEF expression in BS/GS underlines a major impact of RhoA/ROK pathway on blood pressure regulation and confirms BS/GS as a good human model for exploring mechanisms involved in the pathophysiology of hypertension and remodeling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182110     DOI: 10.1016/j.amjhyper.2005.03.747

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

Review 1.  Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension.

Authors:  Verdiana Ravarotto; Elisa Pagnin; Antonio Fragasso; Giuseppe Maiolino; Lorenzo A Calò
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-03-11

Review 2.  Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.

Authors:  L A Calò; G Maiolino
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

3.  High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?

Authors:  L A Calò; R Montisci; R Scognamiglio; P A Davis; E Pagnin; S Schiavo; P Mormino; A Semplicini; P Palatini; A D'Angelo; A C Pessina
Journal:  J Endocrinol Invest       Date:  2009-07-14       Impact factor: 4.256

4.  Signaling through Rho GTPase pathway as viable drug target.

Authors:  Qun Lu; Frank M Longo; Huchen Zhou; Stephen M Massa; Yan-Hua Chen
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

5.  Angiotensin II regulates the LARG/RhoA/MYPT1 axis in rat vascular smooth muscle in vitro.

Authors:  Wei-chiao Chiu; Jyh-ming Juang; Shen-nan Chang; Cho-kai Wu; Chia-ti Tsai; Yung-zu Tseng; Fu-tien Chiang
Journal:  Acta Pharmacol Sin       Date:  2012-11-05       Impact factor: 6.150

6.  Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract.

Authors:  Cleber E Teixeira; Liming Jin; Fernanda B M Priviero; Zhekang Ying; R Clinton Webb
Journal:  Biochem Pharmacol       Date:  2007-06-07       Impact factor: 5.858

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.